Ailing Novo Seeks Cure With Diabetes Drug That May Fight Fat Too

[Northerner]

Novo Nordisk A/S has a potent new medicine that Chief Executive Officer Lars Fruergaard Jorgensen is counting on to nurse the drugmaker back to health.

The experimental treatment, called semaglutide, should go on sale next year as an injection for diabetes. But that’s only the first step of Novo’s development plan: Its scientists are working on a patient-friendly tablet version of the drug that could reach pharmacy shelves in 2020. They’re also testing the product for a form of liver disease, a market that some analysts say may eventually be worth $35 billion in sales, and obesity.

As a slimming medicine alone, its effect could get closer to the results delivered by bariatric surgery, Jorgensen said in an interview. The drug is expected to reach annual sales of almost $10 billion over the next decade, even before taking into account its potential use as an obesity treatment, according to Nordea estimates, providing a much-needed boost for the Danish company. Only one drug in the entire pharmaceutical industry exceeded that last year.

https://www.bloomberg.com/news/arti...ure-with-diabetes-drug-that-may-fight-fat-too

 

[Matt Cycle]

Ailing Novo? They still make billions. And I wish they'd get their facts correct when writing these articles as they're talking about Type 2 diabetes. I've got diabetes but this product would be neither use nor ornament to me. I certainly don't need to lose any weight either. 🙄

 

[mikeyB]

I agree with Matt. This just a business puff to boost their share price on the back of a me too drug that happens to suppress appetite. If it's anything like the others, it does that by making you throw up.

 

[prc62]

Ive been on it for 3 months and the only way I can see it working is by slowing down the digestive system. Not sure I will continue. Certainly feeling very sluggish and haven't experienced any dramatic weight loss. Do feel that I am putting a very powerful chemical into my body.

 

[martindt1606]

Novo Nordisk A/S has a potent new medicine that Chief Executive Officer Lars Fruergaard Jorgensen is counting on to nurse the drugmaker back to health.

The experimental treatment, called semaglutide, should go on sale next year as an injection for diabetes. But that’s only the first step of Novo’s development plan: Its scientists are working on a patient-friendly tablet version of the drug that could reach pharmacy shelves in 2020. They’re also testing the product for a form of liver disease, a market that some analysts say may eventually be worth $35 billion in sales, and obesity.

As a slimming medicine alone, its effect could get closer to the results delivered by bariatric surgery, Jorgensen said in an interview. The drug is expected to reach annual sales of almost $10 billion over the next decade, even before taking into account its potential use as an obesity treatment, according to Nordea estimates, providing a much-needed boost for the Danish company. Only one drug in the entire pharmaceutical industry exceeded that last year.

https://www.bloomberg.com/news/arti...ure-with-diabetes-drug-that-may-fight-fat-too

How far off is this tablet that in 2017 was going to hit the shelves this year?

 

[everydayupsanddowns]

How far off is this tablet that in 2017 was going to hit the shelves this year?

We already have several members starting on or asking about Ozempic/Semaglutide injections Martin.

I think the tablets launched in 2019

Semaglutide | Drugs | BNF content published by NICE

View semaglutide information, including dose, uses, side-effects, renal impairment, pregnancy, breast feeding, contra-indications and important safety information.

bnf.nice.org.uk

DEFINE_ME